Guillain-Barré Syndrome After Receiving the First Dose of Oxford–AstraZeneca SARS-CoV-2 Vaccine

Hossein Mozhdehipanah; Shirin Mavandadi; Sepideh Paybast

doi:10.18502/acta.v60i6.10045

Hossein Mozhdehipanah Department of Neurology, Bou Ali Sina Hospital, Qazvin University of Medical Sciences, Qazvin, Iran
Shirin Mavandadi Department of Neurology, Bou Ali Sina Hospital, Qazvin University of Medical Sciences, Qazvin, Iran
Sepideh Paybast Department of Neurology, Neuroscience Research Center, Qom University of Medical Sciences and Health, Qom, Iran

DOI: https://doi.org/10.18502/acta.v60i6.10045

Keywords: Coronavirus disease 2019 (COIVD-19); Vaccine; Oxford-AstraZeneca vaccine; Guillain-barré syndrome (GBS)

Abstract

Safety monitoring of COVID-19 vaccination is paramount of importance. There are limited reports of Guillain-Barré syndrome (GBS) associated with the COVID-19 vaccination. The present study reported a case of GBS following the first dose of the Oxford-AstraZeneca SARS-CoV-2 vaccine. A 32-year-old man presented a history of progressive descending weakness and autonomic features within a month after receiving the Oxford-AstraZeneca SARS-CoV-2 vaccine. The neurological examination was consistent with acute polyneuropathy. The para-clinical investigations were in favor of acute demyelinating polyneuropathy. The patient was diagnosed with GBS, and IVIG was initiated as an acute treatment, which led to significant clinical recovery. We reported a case of GBS after receiving the Oxford-AstraZeneca vaccine. However, our findings dose not conclude a causal association between GBS and COVID-19 vaccination.